孟加拉国耐药志贺菌病阿奇霉素治疗的临床结局
在孟加拉国开展观察性队列研究,纳入149例志贺菌培养阳性的侵袭性腹泻患者,均经验性使用阿奇霉素治疗。结果显示,对阿奇霉素敏感性降低的志贺菌感染与第5天腹泻持续、第5或6天培养阳性及更高的过夜住院率显著相关;宋内志贺菌是耐药和不良结局的主要关联菌种。
要点
- 阿奇霉素敏感性降低的志贺菌感染与第5天腹泻持续风险升高相关(31% vs 12%)。
- 宋内志贺菌多表现为阿奇霉素敏感性降低和多重耐药,且与不良临床结局相关。
- 福氏志贺菌阿奇霉素敏感性降低的流行病学折点(≥16 µg/mL)可预测不良结局。
核心结论
- 福氏志贺菌对阿奇霉素敏感性降低及宋内志贺菌感染均与更差的临床结局相关,支持开展药敏试验并应用阿奇霉素临床折点。
- 宋内志贺菌是新兴的耐药威胁。
研究设计与样本
- 在孟加拉国开展观察性队列研究,纳入149例志贺菌培养阳性的侵袭性腹泻患者,均经验性接受阿奇霉素治疗。
- 对所有志贺菌分离株事后进行肉汤微量稀释法和纸片扩散法药敏试验,并将临床应答与体外敏感性进行关联分析。
主要发现
- 对阿奇霉素敏感性降低的志贺菌感染与第5天腹泻持续显著相关(31% vs 12%;RR 2.66;95%CI 1.34-5.28)。
- 对阿奇霉素敏感性降低的志贺菌感染与第5或6天培养阳性显著相关(35% vs 5%;RR 5.26;95%CI 1.84-14.85)。
- 对阿奇霉素敏感性降低的志贺菌感染与更高的过夜住院率显著相关(58% vs 39%;RR 1.49;95%CI 1.06-2.09)。
- 福氏志贺菌比宋内志贺菌更常见(58% vs 36%),但宋内志贺菌占阿奇霉素敏感性降低分离株的67%和多重耐药菌株的54%。
- 宋内志贺菌且阿奇霉素MIC低至4 µg/mL的患者仍有较高的持续性腹泻和培养阳性率。
关键数值与推荐
- 福氏志贺菌对阿奇霉素敏感性降低的当前流行病学折点为≥16 µg/mL,该折点可临床预测不良结局。
临床怎么用
- 对志贺菌感染应考虑进行阿奇霉素药敏试验,并结合临床折点解读结果以指导治疗。
- 宋内志贺菌感染需警惕阿奇霉素敏感性降低及不良临床结局的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Azithromycin is frequently used to treat shigellosis; however, clinical outcomes are uncertain. METHODS: We performed an observational cohort study in Bangladesh of patients with invasive diarrhea treated empirically with azithromycin. Susceptibility testing was performed by broth microdilution and disk diffusion post hoc on all Shigella isolates and clinical response was correlated with in vitro susceptibility. RESULTS: There were 149 Shigella culture-positive patients in the primary analysis. Infection with Shigella with decreased susceptibility to azithromycin was significantly associated with persistence of diarrhea at day 5 (31% vs 12%; relative risk [RR], 2.66; 95% confidence interval [CI], 1.34-5.28), culture positivity at day 5 or 6 (35% vs 5%; RR, 5.26; 95% CI, 1.84-14.85), and a higher rate of overnight hospitalization (58% vs 39%; RR, 1.49; 95% CI, 1.06-2.09). Shigella flexneri was more common than Shigella sonnei (58% vs 36%); however, S. sonnei constituted most of the isolates with decreased susceptibility to azithromycin (67%) and most of the multidrug-resistant strains (54%); thus, poor clinical outcomes were associated with S. sonnei. The current epidemiological cutoff for S. flexneri of ≥16 µg/mL to define decreased susceptibility to azithromycin was clinically predictive of poor outcome. Patients with S. sonnei and a low MIC (4 µg/mL) still had elevated rates of persistent diarrhea and culture positivity. CONCLUSIONS: This study documents worse clinical outcomes for S. flexneri with decreased susceptibility to azithromycin, as well as S. sonnei, and supports the utility of susceptibility testing and clinical breakpoints for azithromycin. S. sonnei is an emerging drug-resistant threat. CLINICAL TRIALS REGISTRATION: NCT03778125.
引用
- Houpt ER, Ferdous T, Ara R, et al. Clinical Outcomes of Drug-resistant Shigellosis Treated With Azithromycin in Bangladesh. Clin Infect Dis. 2021. PMID: 32239137. doi:10.1093/cid/ciaa363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。